Tocilizumab wins over Prednisone in Patients with Active Polymyalgia Rheumatica: JAMA
Tocilizumab usage in active polymyalgia rheumatica patients resulted in a polymyalgia rheumatica activity score computed using the C-reactive protein level (CRP PMR-AS) less than 10 in a significantly greater number of patients. Prednisone requirement has also reduced at week 24 as per a study that was published in the journal JAMA Network.
There are not so many treatments for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists can reduce disease activity in patients with active glucocorticoid-dependent polymyalgia rheumatica. Hence researchers compared the efficacy of tocilizumab vs placebo in patients with glucocorticoid-dependent polymyalgia rheumatica from February 2017 to October 2019.
A double-blind, parallel-group, placebo-controlled randomized clinical trial was carried out on 101 patients with polymyalgia rheumatica at 17 hospitals in France. Patients with persistent disease activity having a CRP PMR-AS score >10 and prednisone dose greater than or equal to 10 mg per day were taken. They were randomly assigned to receive intravenous tocilizumab of 8 mg/kg or placebo every 4 weeks for 24 weeks, combined with predefined standardized tapering of oral prednisone. The primary efficacy endpoint was CRP PMR-AS less than 10 combined with either prednisone dose less than or equal to 5 mg per day or a decrease in prednisone dose greater than or equal to 10 mg from baseline at week 24. There were 11 secondary outcomes assessed at week 24 like the disease activity as measured by CRP PMR-AS and the proportion of patients no longer taking prednisone.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.